AstraZeneca’s Calquence Showed Improvement In Small Group Of Hospitalized Covid-19 Patients

Late in the afternoon on the first Friday of April, Andrew Monticelli, an oncologist at Rocky Mountain Cancer Centers, got a phone call from Jeff Sharman, the medical director of hematology research for McKesson’s U.S. Oncology. Sharman said that a blood cancer drug Monticelli knew well, AstraZeneca’s Calquence, could potentially help later-stage Covid-19 patients.